[1]刘延梅a,马少君b,马庆a,等.非小细胞肺癌患者组织EGFR基因突变状况及预后分析[J].现代检验医学杂志,2019,34(01):22-25.[doi:10.3969/j.issn.1671-7414.2019.01.006]
LIU Yan-meia,MA Shao-junb,MA Qinga,et al.Analysis of the Status and Outcome of Epidermal Growth
Factor Receptor Mutations in Non-Small Cell Lung Cancer Patients[J].Journal of Modern Laboratory Medicine,2019,34(01):22-25.[doi:10.3969/j.issn.1671-7414.2019.01.006]
点击复制
非小细胞肺癌患者组织EGFR基因突变状况及预后分析(
)
《现代检验医学杂志》[ISSN:/CN:]
- 卷:
-
第34卷
- 期数:
-
2019年01期
- 页码:
-
22-25
- 栏目:
-
论著
- 出版日期:
-
2019-02-28
文章信息/Info
- Title:
-
Analysis of the Status and Outcome of Epidermal Growth
Factor Receptor Mutations in Non-Small Cell Lung Cancer Patients
- 文章编号:
-
1671-7
414(2019)01-022-04
- 作者:
-
刘延梅a; 马少君b; 马庆a; 张静a
-
(陕西省人民医院a.西院二病区；b.放射科，西安710068)
- Author(s):
-
LIU Yan-meia; MA Shao-junb; MA Qinga; ZHANG Ji
nga
-
( a .the Second Ward of West Deparment；
b .Department of Radiology，Shaanxi Provincial People’s Hospital，Xi
’an 710068，China)
-
- 关键词:
-
表皮生长因子受体突变; 非鳞状非小细胞肺癌; 酪氨酸激酶抑
制剂
- 分类号:
-
R734.2；R730.43
- DOI:
-
10.3969/j.issn.1671-7414.2019.01.006
- 文献标志码:
-
A
- 摘要:
-
目的分析非小细胞肺癌(NSCLC)患者组织表皮生长因子受
体(EGFR)基因突变状况、临床病理相关性以及表皮生长因子受体(epidermal growth factor
receptor，EGFR)的酪氨酸激酶抑制剂(tyrosine kinase inhibitors，TKI)EGFR -TKIs治
疗的结果。方法选取陕西省人民医院2014年1月～2017年5月一线口
服EGFR-TKIs并进行EGFR检测的NSCLC患者111例，分析患者EGFR基因的突变状态、临床病理
特征及对患者进行长期随访并评价预后。结果在111个被评估样本
中，EGFR基因突变34例(30.6%)，女性明显高于男性，差异具有统计学意义(44% vs 19.7%
， χ2=7.65，P =0.007 2)。吸烟者明显高于不吸烟者，差异具有统计学意义(41.4
% vs 12.2%， χ2=10.40，P =0.001 3)。其中外显子19缺失突变19例(71%)，外显
子21点突变21例(25%)。肺腺癌EGFR突变率明显高于非腺癌的NSCLC，差异具有统计学意义(3
4.7% vs 6.3%， χ2=5.29，P =0.018)。使用一线TKIs治疗患者中，EGFR基因突变
患者中位无进展生存时间(progress free survival，PFS)明显长于野生型患者，差异具有
统计学意义(10个月 vs 3个月， P <0.000 1)，EGFR基因突变患者中位总生存时间(over
all survival，OS)明显长于野生型患者，差异具有统计学意义(20个月 vs 9个月， P =0
.000 2)。结论NSCLC患者进行EGFR基因突变检测具有重要性，EGF
R基因突变与性别及吸烟状况相关，EGFR基因状态可为EGFR-TKIs的一线治疗提供有效依据
，EGFR基因突变患者一线EGFR-TKIs口服治疗的预后优于野生型患者。
- Abstract:
-
Objective To evaluate the status of EGFR mutati
ons in patients with NSCLC，clinico-pathological correlation and outcome to tre
atment with EGFR TKIs．Methods A total of 111 NSCLC patie
nts with advanced oral EGFR-TKIs in Shaanxi Provincial People’s Hospital from
January 2014 to May 2017 were tested for EGFR gene mutation status，clinicopa
thologic features，and all patients were received long-term follow-up and prog
nos
is evaluation．Results EGFR mutations were seen in 30.6%
of the 111 evaluable specimens，with a significantly higher rate in females (44
% vs 19.7%， χ2=7.65，P =0.007 2) as compared to men and non-smokers (4
1.4% vs 12.2%， χ2=10.40，P =0.001 3) as against smokers．Most common m
utations were observed in exons 19 (71%) and 21 (25%)．The EGFR mutation rate in
p
atients with lung adenocarcinoma was significantly higher than that of patients
with other no-adenocarcinoma types of NSCLC (34.7% vs 6.3%， χ2=5.29，P
=0.018)．The estimated median progression free survival for patients with and
without mutations when treated with upfront TKIs was 12 months and 3 months res
pectively and the estimated median overall survival for patients with and withou
t mutations was 20 and 9 months respectively．There were significant difference
in PFS and OS ( P<0.000 1，P=0.000 2)．Conclusion Th
is study further establishes the importance of upfront EGFR mutation testing in
all NSCLC patients，the status of the mutation of EGFR gene were related to gend
er and smoking status，which can predict abenefit from EGFR-TKIs given as first
-line therapy，and the prognosis of first-line oral egfr-tkis is better than
that of wild-type patients．
参考文献/References:
[1］CHEN Wanqing，ZHWNG Rongshou，BAADE P D，et al．Cancer statistics
in China 2015［J］．CA A Cancer J Clin，2016，66(2)：115- 132．
[2］RECK M，HEIGENER D F，MOK T，et al．Management of non-smal cell lung can
cer：recent developments［J］．Lancet，2013，382(9893)：709-719．
[3］SIEGEL R L，MILLER K D，JEMAL A．Cancer statistics，2015［J］．CA：A Canc
er Journal for Clinicians，2015，65 (1)：5-29．
[4］SHARMA S V，BELL D W，SETTLEMAN J，et al．Epidermal growth factor recepto
r
mutations in lung cancer［J］．Nat Rev Cancer，2007，7(3)：169-181．
[5］LYNCH T J，BELL D W，SORDELLA R，et al．Activating muta
tions in the epidermal growth factor receptor underlying responsiveness of non-
small-cell lung cancer to gefitinib［J］．N Engl J Med，2004，350(2)：2129-213
9．
[6］PAEZ J G，JNNE P A，LEE J C，et al．EGFR mutations in lung cance
r
： Correlation with clinical response to gefitinib therapy［J］．Science，2004，
304(5676)：1497-1500．
[7］喻晶，李运雷，刘晓翌．非小细胞肺癌患者不同类型样本中表皮生长因子受体基因
突变的差异研究［J］．现代检验医学杂志，2018，33(4)：31-33．
YU Jing，LI Yunlei，LIU Xiaoyi，et al．Detection of epidermal growth
factor receptor gene mutation in different sample types of 238 patients with no
n-small cell lung cance［J］．Journal of Modern Laboratory Medicine，2018，33(4
)：31-33．
[8］张永庆，尚立群，苗毅，等．表皮生长因子受体基因突变与非小细胞肺癌病理的
相关性分析［J］．现代检验医学杂志，2017，32(6)：78-80．
ZHANG Yongqing，SHANG Liqun，MIAO Yi，et al．Analysis of the correla
tion between mutations of the epidermal growth factor receptor gene and patholog
ical of non small cell lung cancer［J］．Journal of Modern Laboratory Medicine，
2017，32(6)：70-80．
[9］DOGAN S，SHEN R，ANG D C，et al．Molecular epidemiology of EGFR and KRAS
mutations in 3 026 lung adenocarcinomas：Higher susceptibility of women to smoki
ng-related KRAS-mutant cancers［J］．Clin Cancer Res，2012，18(22)：6169-6177
．
[10］WU Yilong，ZHONG Wenzhao，LI Longyun，et al．Epidermal growth fa
ctor receptor mutations and their correlation with gefitinib therapy in patients
with non-small cell lung cancer：A meta-analysis based on updated individual
patient data from six medical centers in mainland China［J］．J Thorac Oncol，20
07，2(5)：430-439．
[11］D’ANGELO S P，PIETANZA M C，JOHNSON M L，et al．Incidence of EGFR exon
19 deletions and L858R in tumor specimens from men and cigarette smokers with lu
ng adenocarcinomas［J］．J Clin Oncol，2011，29(15)：2066-2070．
[12］NORONHA V，PRABHASH K，THAVAMANI A，et al．EGFR mutations in indian lung
cancer patients：Clinical correlation and outcome to EGFR targeted therapy［J］
．PLoS One，2013，8(4)：e61561
备注/Memo
- 备注/Memo:
-
基金项目：
陕西省自然科学基金项目(编号：2017JM8174)，陕西科学技术研究发展计划项目(
编号：2012K-16-01-01)。
作者简介：刘延梅(1976-)，女，副主任医师，从事呼
吸、内分泌、老年病治疗工作，E-mail：ma20020407@163.com。
通讯作者：马少君(1975-)，男，副主任医师，从事呼吸、消化疾
病影像诊断工作。
更新日期/Last Update:
2019-02-28